were dropping double digits after analysts at Canaccord downgraded the company's Canadian-traded stock to sell while maintaining its C$17 price target. invested C$2.4 billion in the company, but analyst Matt Bottomley said this has stretched the company's valuation. "With Altria's C$2.4B investment now in the books, Cronos indicated that it intends to use the proceeds to accelerate its global growth initiatives, including its human capital, distribution footprint, branding, R&D and product formulation capabilities," Bottomley wrote.